Association persisted after removing patients with previous diagnosis of gastroesophageal reflux
THURSDAY, Dec. 4, 2025 (HealthDay News) — For patients with type 2 diabetes, there is an association between glucagon-like peptide-1 receptor agonist (GLP-1 RA) use and chronic cough, according to a study published online Nov. 26 in JAMA Otolaryngology-Head & Neck Surgery.
Tyler J. Gallagher, M.D., M.P.H., from the Keck School of Medicine at the University of Southern California in Los Angeles, and colleagues examined the clinical association between GLP-1 RAs and chronic cough in a large multicenter cohort study using electronic medical record data from 70 health care organizations. Adults with type 2 diabetes and prescription of a GLP-1 RA were identified and compared to those prescribed another second-line diabetes medication (cohorts included 427,555 and 1,614,495 participants, respectively).
The researchers found that individuals prescribed a GLP-1 RA had a significantly increased risk for new chronic cough compared with those prescribed any non-GLP-1 RA second-line medication, dipeptidyl peptidase-4 (DPP-4) inhibitor, or sulfonylurea in a propensity score-matched analysis (adjusted hazard ratios, 1.12, 1.18, and 1.32, respectively). This finding was not seen compared with those prescribed a sodium-glucose cotransporter 2 (SGLT2) inhibitor. After removing patients with a previous diagnosis of gastroesophageal reflux, those prescribed GLP-1 RAs had a significantly increased risk for chronic cough compared with those prescribed any non-GLP-1 RA, DPP-4 inhibitor, SGLT2 inhibitor, or sulfonylurea (adjusted hazard ratios, 1.29, 1.36, 1.14, and 1.25, respectively).
“This cohort study suggests that there is an association between GLP-1 receptor agonist use and new diagnosis of chronic cough,” the authors write. “This association was present even among patients without a diagnosis of gastroesophageal reflux disease.”
Abstract/Full Text (subscription or payment may be required)
Weight-Loss Surgery Produces Lasting Diabetes Remission
Pregnancy Complications Linked to Subsequent Risk for Cardiometabolic-Renal Conditions
GLP-1 Receptor Agonists, SGLT-2is Slow Renal Function Decline in T2D With Albuminuria
Study IDs Risk Factors for Ketoacidosis in Adults With T2D Receiving SGLT2 Inhibitors
Study IDs Real-World Reasons for Lemborexant Discontinuation
Treatment Satisfaction Higher for Patients With RA Choosing Their Own Treatment
Most Specialty Oral Anticancer Meds for Blood Cancers Are Initially Rejected by Insurers
Drug Interactions Reducing Contraceptive Effectiveness Common in Epilepsy